Technical Analysis for NBIX - Neurocrine Biosciences, Inc.

Grade Last Price % Change Price Change
grade B 101.5 0.38% 0.38
NBIX closed up 0.38 percent on Thursday, September 19, 2019, on 72 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical NBIX trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
MACD Bullish Signal Line Cross Bullish 0.38%
NR7 Range Contraction 0.38%
Stochastic Reached Overbought Strength 0.38%
Upper Bollinger Band Walk Strength 0.38%

Older signals for NBIX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Chemistry Pain Diabetes Disorders Schizophrenia Alcohols Cardiovascular Diseases Hormones Epilepsy Ethers Movement Disorders Ii Diabetes Pyrimidines Gnrh Antagonists Endometriosis Gonadotropin Releasing Hormone Antagonist Insomnia Uterine Fibroids
Is NBIX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 125.59
52 Week Low 64.72
Average Volume 644,707
200-Day Moving Average 85.1468
50-Day Moving Average 94.3318
20-Day Moving Average 98.114
10-Day Moving Average 98.196
Average True Range 3.0844
ADX 30.78
+DI 23.9684
-DI 13.1735
Chandelier Exit (Long, 3 ATRs ) 93.1068
Chandelier Exit (Short, 3 ATRs ) 101.6932
Upper Bollinger Band 101.9929
Lower Bollinger Band 94.2351
Percent B (%b) 0.94
BandWidth 7.906925
MACD Line 1.4227
MACD Signal Line 1.2734
MACD Histogram 0.1493
Fundamentals Value
Market Cap 8.95 Billion
Num Shares 88.2 Million
EPS -2.52
Price-to-Earnings (P/E) Ratio -40.28
Price-to-Sales 826.51
Price-to-Book 15.16
PEG Ratio 1.78
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 103.68
Resistance 3 (R3) 103.72 103.04 103.31
Resistance 2 (R2) 103.04 102.49 103.02 103.19
Resistance 1 (R1) 102.27 102.14 102.66 102.23 103.07
Pivot Point 101.59 101.59 101.78 101.57 101.59
Support 1 (S1) 100.82 101.04 101.21 100.78 99.93
Support 2 (S2) 100.14 100.69 100.12 99.81
Support 3 (S3) 99.37 100.14 99.69
Support 4 (S4) 99.33